has developed a new biomaterial with high potential in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The findings showcase a promising approach to bone ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients.

The team tackled a critical challenge in treating multiple myeloma-a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Myeloma develops due to the accumulation of multiple pathological genetic events ... chain variable region constitute primary genetic lesions. These primary lesions co-operate with secondary ...

The team tackled a critical challenge in treating multiple myeloma -- a blood cancer where malignant plasma cells accumulate in bone marrow, leading to debilitating bone lesions in 80% of patients.

Early treatment with intravenous bisphosphonates at first radiographic evidence of bone lesions in patients with solid tumors or evidence of osteopenia in patients with multiple myeloma can ...